Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amgen, Inc.
Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.
The company published data for the bispecific antibody in wet AMD and DME, with non-inferior efficacy to Eylea and growing support for less frequent administration.
While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.
Medtech Insight spoke to the chief financial officer of Ligence, a Lithuanian start-up developing AI for echocardiography, to find out more about its commercial strategy, and problems it faces with commercialization.
- Other Names / Subsidiaries
- Amgen Astellas BioPharma K.K.
- Amgen K.K.
- BioVex Group
- Catherex, Inc.
- deCODE Genetics
- Dezima Pharma B.V.
- Five Prime Therapeutics, Inc.
- Immunex Corporation
- KAI Pharmaceuticals
- Kirin-Amgen Inc.
- Laboratorio Quimico Farmaceutico Bergamo Ltd
- Micromet, Inc. (CancerVax Corporation)
- Nuevolution AB
- Nuevolution A/S
- Onyx Pharmaceuticals, Inc. (Proteolix, Inc.)
- Saga Investments LLC